BioSpace News Archive

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that it presented four oral presentations and two poster presentations on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the International Society on Thrombosis and Haemostasis (ISTH) 2022 World Congress from July 9-12 in London.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced its preliminary unaudited financial results for fiscal year ended April 30, 2022.

ThinkCyte Inc., a biotechnology company pioneering novel cell analysis and sorting instruments, announced that applications of its Ghost Cytometry technology were presented at several leading industry meetings.

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the CE Mark submission for its MAGiC™ catheter.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has shipped testing reagents for monkeypox virus currently exhibiting a multi-country outbreak to one of its international distributors.

Dr. Marvin S. Hausman, the Chairman of NOVA’s Scientific Advisory Board, will deliver a presentation titled: A Novel Psilocybin Microdose Treatment of Fragile X Syndrome.

Samsara Vision, a company focused on bringing vision and freedom back to patients with late-stage, age-related macular degeneration (AMD) through advanced visual prosthetic devices, today announced the completion of the first U.S. surgeries of its SING IMT™ (Smaller-Incision New-Generation Implantable Miniature Telescope).

Oxurion NV a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced participation in two upcoming conferences.

The global cancer biomarker market size is expected to reach USD 118.08 Billion in 2030 and register a revenue CAGR of 17.6% over the forecast period, according to the latest report by Reports and Data.

Cervical cancer is the fourth-most common cancer and cause of cancer deaths in women worldwide.